Sai Life Sciences , a prominent player in the pharmaceutical industry, has announced the allotment of 8,89,133 fully paid-up equity shares under its employee stock option plans. This move, approved by the company's Board of Directors through a circular resolution dated December 19, 2025, aims to attract, retain, and reward employees.

Details of the Latest Allotment

The recent allotment includes shares issued under two distinct employee stock option plans with significantly higher numbers than previous allotments:

Updated Share Capital Structure

Following this substantial allotment, Sai Life Sciences' total issued share capital has increased significantly to 21,12,31,216 shares. The newly allotted shares have been issued in dematerialized form with the ISIN number INE570L01029, with distinctive numbers ranging from 210342084 to 211231216.

Premium and Pricing Details

The company has structured the allotment with specific premium components:

Employee Stock Option Plans Framework

The company's employee stock option plans, ESOP 2008 and MESOP 2018, are designed with a maximum vesting period of 5 years. These plans offer flexibility with multiple vesting options, allowing employees to exercise their options as long as they remain in the company's service. The pricing formula is determined by the Nomination and Remuneration Committee in conformity with applicable accounting standards and SEBI regulations.

Regulatory Compliance and Documentation

Sai Life Sciences has ensured comprehensive compliance with regulatory requirements, filing necessary documents with both BSE Limited and National Stock Exchange of India Limited. The company has adhered to the Securities and Exchange Board of India (SEBI) regulations, including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

This substantial allotment of shares under the employee stock option plans demonstrates Sai Life Sciences' continued commitment to aligning employee interests with the company's long-term growth objectives and talent retention strategy.

Sai Life Sciences Limited has released its sixth sustainability report for FY2024-25, demonstrating the company's commitment to responsible growth and environmental stewardship. The report, aligned with Global Reporting Initiative (GRI) Universal Standards 2021 and Sustainability Accounting Standards Board (SASB) standards, is presented under the theme "Driving climate action, deepening stakeholder trust."

Strategic Framework and Sustainability Pillars

The company's sustainability strategy is anchored in nine strategic pillars that collectively guide its approach to responsible growth. These comprehensive elements span multiple areas of operation and stakeholder engagement:

These elements constitute a cohesive framework that embeds sustainability priorities into every stage of the company's operations, aligning with business objectives and stakeholder expectations.

Key Performance Achievements

The report highlights significant progress across multiple sustainability metrics during FY2024-25. The company advanced its internally defined Sustainable Development Goals (SDGs), which outline a clear roadmap for meeting sustainability commitments by March 31, 2027.

Environmental Progress

Social Impact and Community Engagement

Sai Life Sciences demonstrated substantial community impact, surpassing its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities. The organization also strengthened its people agenda with steady growth in diversity initiatives.

Leadership Perspective and Future Outlook

Krishna Kanumuri, MD & CEO of Sai Life Sciences, emphasized the company's commitment to reliability with responsibility as central to the CRDMO mandate. He highlighted the translation of this commitment into action through progress across climate actions, circular economy initiatives, people-led HR transformation, and tech-enabled innovation.

The company is focused on scaling these efforts to build a resilient, science-forward, and sustainability-led operating model that delivers enduring value to partners and stakeholders. The 2024-25 sustainability report reflects the company's long-term view that places science, responsibility, and collaboration at the center of its growth ambition.

Regulatory Compliance and Reporting

The sustainability report release was announced pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This sixth edition continues the company's commitment to transparent reporting and stakeholder communication regarding its sustainability initiatives and progress.

As Sai Life Sciences continues to expand its global footprint with operations across India, the UK, and the US, sustainability remains both a compass and a catalyst for shaping resilient, future-ready operations in the contract research, development, and manufacturing sector.

The report highlights the company's progress in climate action, increased renewable energy usage, and impactful community initiatives, aligning with its commitment to responsible growth and environmental stewardship.